Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Izalontamab brengitecan - Bristol-Myers Squibb

Next Previous
Drug Profile

Izalontamab brengitecan - Bristol-Myers Squibb

Alternative Names: BL-B01D1; BMS-986507; EGFRxHER3 ADC; Iza-bren - Bristol-Myers Squibb

Latest Information Update: 06 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Baili Pharmaceutical; SystImmune
  • Developer Bristol-Myers Squibb; Sichuan Baili Pharmaceutical; SystImmune
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HER2 negative breast cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer; Urogenital cancer
  • Phase II Cervical cancer; Colorectal cancer; Gastric cancer; Glioblastoma; Oesophageal cancer; Solid tumours; Triple negative breast cancer
  • No development reported Gastrointestinal cancer

Most Recent Events

  • 29 May 2025 Sichuan Baili Pharmaceutical plans a phase III trial to Ovarian cancer (Recurrent) in China (IV, Infusion) (NCT06994195)
  • 23 May 2025 Sichuan Baili Pharmaceutical plans a phase II trial for Liver cancer (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease) in China in June 2026 (IV) (NCT06986785)
  • 18 May 2025 Sichuan Baili Pharmaceutical plans a phase II trial for Biliary Cancer (Late-stage disease, Second-line therapy or greater) in China (IV) (NCT06978114)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top